Industry Research Reports
Raibizumab Biosimilars - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Industry: Pharma & Healthcare
Published Date: 2024-01-11
Pages: 165 Pages
Report ld: 3032128
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion. Ranibizumab was developed by Genentech and marketed by them in the United States, and elsewhere by Novartis, under the brand name Lucentis.
The global market for Raibizumab Biosimilars was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
MARKET SEGMENTATION
By Company
- Roche
- Novartis
- Genentech
- Pfizer
- Sartorius
- Eli Lilly
- Bayer
- Amgen
- PlantForm
- PharmaPraxis
- Samsung Bioepis
- Centus
- Cadila Pharmaceuticals
- Dr Reddy's
- Aurobindo Pharma
- Biocad
- MAbxience
- Hetero
- Biocon
- Kirin Biologics
- Mylan
- BeiGene
- Innovent
- Qilu Pharmaceutical
- Hengrui Pharmaceuticals
- Hisun Pharmaceutical
- TOT BIOPHARM
- Luye Pharmaceutical
- Henlius
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- AMD
- CNV
- DME
Segment by Application
- ARMD
- Diabetic Retinopathy
- Macular Edema
REPORT SCOPE
This report aims to provide a comprehensive presentation of the global market for Raibizumab Biosimilars, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Raibizumab Biosimilars by region & country, by Type, and by Application.
The Raibizumab Biosimilars market size, estimations, and forecasts are provided in terms of sales volume (Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Raibizumab Biosimilars.
CHAPTER OUTLINE
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Raibizumab Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Raibizumab Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Raibizumab Biosimilars in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
We identify regional market threats and growth prospects to guide your overseas layout.
We adjust product portfolios in line with local consumption habits.
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Market Overview
1.1 Raibizumab Biosimilars Product Introduction
1.2 Global Raibizumab Biosimilars Market Size Forecast
1.2.1 Global Raibizumab Biosimilars Sales Value (2019-2030)
1.2.2 Global Raibizumab Biosimilars Sales Volume (2019-2030)
1.2.3 Global Raibizumab Biosimilars Sales Price (2019-2030)
1.3 Raibizumab Biosimilars Market Trends & Drivers
1.3.1 Raibizumab Biosimilars Industry Trends
1.3.2 Raibizumab Biosimilars Market Drivers & Opportunity
1.3.3 Raibizumab Biosimilars Market Challenges
1.3.4 Raibizumab Biosimilars Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Raibizumab Biosimilars Players Revenue Ranking (2023)
2.2 Global Raibizumab Biosimilars Revenue by Company (2019-2024)
2.3 Global Raibizumab Biosimilars Players Sales Volume Ranking (2023)
2.4 Global Raibizumab Biosimilars Sales Volume by Company Players (2019-2024)
2.5 Global Raibizumab Biosimilars Average Price by Company (2019-2024)
2.6 Key Manufacturers Raibizumab Biosimilars Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Raibizumab Biosimilars Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Raibizumab Biosimilars
2.9 Raibizumab Biosimilars Market Competitive Analysis
2.9.1 Raibizumab Biosimilars Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Raibizumab Biosimilars Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Raibizumab Biosimilars as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 AMD
3.1.2 CNV
3.1.3 DME
3.2 Global Raibizumab Biosimilars Sales Value by Type
3.2.1 Global Raibizumab Biosimilars Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Raibizumab Biosimilars Sales Value, by Type (2019-2030)
3.2.3 Global Raibizumab Biosimilars Sales Value, by Type (%) (2019-2030)
3.3 Global Raibizumab Biosimilars Sales Volume by Type
3.3.1 Global Raibizumab Biosimilars Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Raibizumab Biosimilars Sales Volume, by Type (2019-2030)
3.3.3 Global Raibizumab Biosimilars Sales Volume, by Type (%) (2019-2030)
3.4 Global Raibizumab Biosimilars Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 ARMD
4.1.2 Diabetic Retinopathy
4.1.3 Macular Edema
4.2 Global Raibizumab Biosimilars Sales Value by Application
4.2.1 Global Raibizumab Biosimilars Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Raibizumab Biosimilars Sales Value, by Application (2019-2030)
4.2.3 Global Raibizumab Biosimilars Sales Value, by Application (%) (2019-2030)
4.3 Global Raibizumab Biosimilars Sales Volume by Application
4.3.1 Global Raibizumab Biosimilars Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Raibizumab Biosimilars Sales Volume, by Application (2019-2030)
4.3.3 Global Raibizumab Biosimilars Sales Volume, by Application (%) (2019-2030)
4.4 Global Raibizumab Biosimilars Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Raibizumab Biosimilars Sales Value by Region
5.1.1 Global Raibizumab Biosimilars Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Raibizumab Biosimilars Sales Value by Region (2019-2024)
5.1.3 Global Raibizumab Biosimilars Sales Value by Region (2025-2030)
5.1.4 Global Raibizumab Biosimilars Sales Value by Region (%), (2019-2030)
5.2 Global Raibizumab Biosimilars Sales Volume by Region
5.2.1 Global Raibizumab Biosimilars Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Raibizumab Biosimilars Sales Volume by Region (2019-2024)
5.2.3 Global Raibizumab Biosimilars Sales Volume by Region (2025-2030)
5.2.4 Global Raibizumab Biosimilars Sales Volume by Region (%), (2019-2030)
5.3 Global Raibizumab Biosimilars Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Raibizumab Biosimilars Sales Value, 2019-2030
5.4.2 North America Raibizumab Biosimilars Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Raibizumab Biosimilars Sales Value, 2019-2030
5.5.2 Europe Raibizumab Biosimilars Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Raibizumab Biosimilars Sales Value, 2019-2030
5.6.2 Asia Pacific Raibizumab Biosimilars Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Raibizumab Biosimilars Sales Value, 2019-2030
5.7.2 South America Raibizumab Biosimilars Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Raibizumab Biosimilars Sales Value, 2019-2030
5.8.2 Middle East & Africa Raibizumab Biosimilars Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Raibizumab Biosimilars Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Raibizumab Biosimilars Sales Value
6.2.1 Key Countries/Regions Raibizumab Biosimilars Sales Value, 2019-2030
6.2.2 Key Countries/Regions Raibizumab Biosimilars Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Raibizumab Biosimilars Sales Value, 2019-2030
6.3.2 United States Raibizumab Biosimilars Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Raibizumab Biosimilars Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Raibizumab Biosimilars Sales Value, 2019-2030
6.4.2 Europe Raibizumab Biosimilars Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Raibizumab Biosimilars Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Raibizumab Biosimilars Sales Value, 2019-2030
6.5.2 China Raibizumab Biosimilars Sales Value by Type (%), 2023 VS 2030
6.5.3 China Raibizumab Biosimilars Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Raibizumab Biosimilars Sales Value, 2019-2030
6.6.2 Japan Raibizumab Biosimilars Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Raibizumab Biosimilars Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Raibizumab Biosimilars Sales Value, 2019-2030
6.7.2 South Korea Raibizumab Biosimilars Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Raibizumab Biosimilars Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Raibizumab Biosimilars Sales Value, 2019-2030
6.8.2 Southeast Asia Raibizumab Biosimilars Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Raibizumab Biosimilars Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Raibizumab Biosimilars Sales Value, 2019-2030
6.9.2 India Raibizumab Biosimilars Sales Value by Type (%), 2023 VS 2030
6.9.3 India Raibizumab Biosimilars Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Roche
7.1.1 Roche Company Information
7.1.2 Roche Introduction and Business Overview
7.1.3 Roche Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Roche Raibizumab Biosimilars Product Offerings
7.1.5 Roche Recent Development
7.2 Novartis
7.2.1 Novartis Company Information
7.2.2 Novartis Introduction and Business Overview
7.2.3 Novartis Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Novartis Raibizumab Biosimilars Product Offerings
7.2.5 Novartis Recent Development
7.3 Genentech
7.3.1 Genentech Company Information
7.3.2 Genentech Introduction and Business Overview
7.3.3 Genentech Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Genentech Raibizumab Biosimilars Product Offerings
7.3.5 Genentech Recent Development
7.4 Pfizer
7.4.1 Pfizer Company Information
7.4.2 Pfizer Introduction and Business Overview
7.4.3 Pfizer Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Pfizer Raibizumab Biosimilars Product Offerings
7.4.5 Pfizer Recent Development
7.5 Sartorius
7.5.1 Sartorius Company Information
7.5.2 Sartorius Introduction and Business Overview
7.5.3 Sartorius Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Sartorius Raibizumab Biosimilars Product Offerings
7.5.5 Sartorius Recent Development
7.6 Eli Lilly
7.6.1 Eli Lilly Company Information
7.6.2 Eli Lilly Introduction and Business Overview
7.6.3 Eli Lilly Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Eli Lilly Raibizumab Biosimilars Product Offerings
7.6.5 Eli Lilly Recent Development
7.7 Bayer
7.7.1 Bayer Company Information
7.7.2 Bayer Introduction and Business Overview
7.7.3 Bayer Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Bayer Raibizumab Biosimilars Product Offerings
7.7.5 Bayer Recent Development
7.8 Amgen
7.8.1 Amgen Company Information
7.8.2 Amgen Introduction and Business Overview
7.8.3 Amgen Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Amgen Raibizumab Biosimilars Product Offerings
7.8.5 Amgen Recent Development
7.9 PlantForm
7.9.1 PlantForm Company Information
7.9.2 PlantForm Introduction and Business Overview
7.9.3 PlantForm Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
7.9.4 PlantForm Raibizumab Biosimilars Product Offerings
7.9.5 PlantForm Recent Development
7.10 PharmaPraxis
7.10.1 PharmaPraxis Company Information
7.10.2 PharmaPraxis Introduction and Business Overview
7.10.3 PharmaPraxis Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
7.10.4 PharmaPraxis Raibizumab Biosimilars Product Offerings
7.10.5 PharmaPraxis Recent Development
7.11 Samsung Bioepis
7.11.1 Samsung Bioepis Company Information
7.11.2 Samsung Bioepis Introduction and Business Overview
7.11.3 Samsung Bioepis Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
7.11.4 Samsung Bioepis Raibizumab Biosimilars Product Offerings
7.11.5 Samsung Bioepis Recent Development
7.12 Centus
7.12.1 Centus Company Information
7.12.2 Centus Introduction and Business Overview
7.12.3 Centus Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
7.12.4 Centus Raibizumab Biosimilars Product Offerings
7.12.5 Centus Recent Development
7.13 Cadila Pharmaceuticals
7.13.1 Cadila Pharmaceuticals Company Information
7.13.2 Cadila Pharmaceuticals Introduction and Business Overview
7.13.3 Cadila Pharmaceuticals Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
7.13.4 Cadila Pharmaceuticals Raibizumab Biosimilars Product Offerings
7.13.5 Cadila Pharmaceuticals Recent Development
7.14 Dr Reddy's
7.14.1 Dr Reddy's Company Information
7.14.2 Dr Reddy's Introduction and Business Overview
7.14.3 Dr Reddy's Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
7.14.4 Dr Reddy's Raibizumab Biosimilars Product Offerings
7.14.5 Dr Reddy's Recent Development
7.15 Aurobindo Pharma
7.15.1 Aurobindo Pharma Company Information
7.15.2 Aurobindo Pharma Introduction and Business Overview
7.15.3 Aurobindo Pharma Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
7.15.4 Aurobindo Pharma Raibizumab Biosimilars Product Offerings
7.15.5 Aurobindo Pharma Recent Development
7.16 Biocad
7.16.1 Biocad Company Information
7.16.2 Biocad Introduction and Business Overview
7.16.3 Biocad Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
7.16.4 Biocad Raibizumab Biosimilars Product Offerings
7.16.5 Biocad Recent Development
7.17 MAbxience
7.17.1 MAbxience Company Information
7.17.2 MAbxience Introduction and Business Overview
7.17.3 MAbxience Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
7.17.4 MAbxience Raibizumab Biosimilars Product Offerings
7.17.5 MAbxience Recent Development
7.18 Hetero
7.18.1 Hetero Company Information
7.18.2 Hetero Introduction and Business Overview
7.18.3 Hetero Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
7.18.4 Hetero Raibizumab Biosimilars Product Offerings
7.18.5 Hetero Recent Development
7.19 Biocon
7.19.1 Biocon Company Information
7.19.2 Biocon Introduction and Business Overview
7.19.3 Biocon Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
7.19.4 Biocon Raibizumab Biosimilars Product Offerings
7.19.5 Biocon Recent Development
7.20 Kirin Biologics
7.20.1 Kirin Biologics Company Information
7.20.2 Kirin Biologics Introduction and Business Overview
7.20.3 Kirin Biologics Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
7.20.4 Kirin Biologics Raibizumab Biosimilars Product Offerings
7.20.5 Kirin Biologics Recent Development
7.21 Mylan
7.21.1 Mylan Company Information
7.21.2 Mylan Introduction and Business Overview
7.21.3 Mylan Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
7.21.4 Mylan Raibizumab Biosimilars Product Offerings
7.21.5 Mylan Recent Development
7.22 BeiGene
7.22.1 BeiGene Company Information
7.22.2 BeiGene Introduction and Business Overview
7.22.3 BeiGene Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
7.22.4 BeiGene Raibizumab Biosimilars Product Offerings
7.22.5 BeiGene Recent Development
7.23 Innovent
7.23.1 Innovent Company Information
7.23.2 Innovent Introduction and Business Overview
7.23.3 Innovent Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
7.23.4 Innovent Raibizumab Biosimilars Product Offerings
7.23.5 Innovent Recent Development
7.24 Qilu Pharmaceutical
7.24.1 Qilu Pharmaceutical Company Information
7.24.2 Qilu Pharmaceutical Introduction and Business Overview
7.24.3 Qilu Pharmaceutical Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
7.24.4 Qilu Pharmaceutical Raibizumab Biosimilars Product Offerings
7.24.5 Qilu Pharmaceutical Recent Development
7.25 Hengrui Pharmaceuticals
7.25.1 Hengrui Pharmaceuticals Company Information
7.25.2 Hengrui Pharmaceuticals Introduction and Business Overview
7.25.3 Hengrui Pharmaceuticals Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
7.25.4 Hengrui Pharmaceuticals Raibizumab Biosimilars Product Offerings
7.25.5 Hengrui Pharmaceuticals Recent Development
7.26 Hisun Pharmaceutical
7.26.1 Hisun Pharmaceutical Company Information
7.26.2 Hisun Pharmaceutical Introduction and Business Overview
7.26.3 Hisun Pharmaceutical Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
7.26.4 Hisun Pharmaceutical Raibizumab Biosimilars Product Offerings
7.26.5 Hisun Pharmaceutical Recent Development
7.27 TOT BIOPHARM
7.27.1 TOT BIOPHARM Company Information
7.27.2 TOT BIOPHARM Introduction and Business Overview
7.27.3 TOT BIOPHARM Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
7.27.4 TOT BIOPHARM Raibizumab Biosimilars Product Offerings
7.27.5 TOT BIOPHARM Recent Development
7.28 Luye Pharmaceutical
7.28.1 Luye Pharmaceutical Company Information
7.28.2 Luye Pharmaceutical Introduction and Business Overview
7.28.3 Luye Pharmaceutical Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
7.28.4 Luye Pharmaceutical Raibizumab Biosimilars Product Offerings
7.28.5 Luye Pharmaceutical Recent Development
7.29 Henlius
7.29.1 Henlius Company Information
7.29.2 Henlius Introduction and Business Overview
7.29.3 Henlius Raibizumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
7.29.4 Henlius Raibizumab Biosimilars Product Offerings
7.29.5 Henlius Recent Development
8 Industry Chain Analysis
8.1 Raibizumab Biosimilars Industrial Chain
8.2 Raibizumab Biosimilars Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Raibizumab Biosimilars Sales Model
8.5.2 Sales Channel
8.5.3 Raibizumab Biosimilars Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
TABLE OF FIGURES
List of Tables
List of Figures
KEY QUESTIONS ADDRESSED BY THE REPORT
Related Reports
Raibizumab Biosimilars- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Raibizumab Biosimilars was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-01-16
Pages: 181
USD 3950.00
(Single User License)
Global Raibizumab Biosimilars Market Research Report 2025
The global market for Raibizumab Biosimilars was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published Date: 2025-01-16
Pages: 126
USD 2900.00
(Single User License)
Global Raibizumab Biosimilars Market Research Report 2024
Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion. Ranibizumab was developed by Genentech and marketed by them in the United States, and elsewhere by Novartis, under the brand name Lucentis.
Published Date: 2024-01-20
Pages: 112
USD 2900.00
(Single User License)
Raibizumab Biosimilars- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Raibizumab Biosimilars was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-01-16
Pages: 181
USD 3950.00 (Single User License)Global Raibizumab Biosimilars Market Research Report 2025
The global market for Raibizumab Biosimilars was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published: 2025-01-16
Pages: 126
USD 2900.00 (Single User License)Global Raibizumab Biosimilars Market Research Report 2024
Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion. Ranibizumab was developed by Genentech and marketed by them in the United States, and elsewhere by Novartis, under the brand name Lucentis.
Published: 2024-01-20
Pages: 112
USD 2900.00 (Single User License)
USD 3950.00
USD 5925.00
USD 7900.00
Add to Cart
Buy Now
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
REPORT SCOPE
CHAPTER OUTLINE
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now